A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
Status:
Completed
Trial end date:
2011-10-27
Target enrollment:
Participant gender:
Summary
A phase 2, multicenter, uncontrolled, open-label trial in participants with Multi-drug
Resistant Tuberculosis (MDR-TB). Only participants who completed Trial 242-07-204
(NCT00685360) were eligible. The trial was performed globally at 14 sites qualified to treat
MDR-TB. All 434 participants who completed Trial 242-07-204 were eligible for this trial if
there was still potential clinical benefit to them and all inclusion criteria and no
exclusion criteria were met.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.